PennyStockChaser.com tracks daily stocks that are on the move, like Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI). We are pleased to offer a stock alert service. Investors who are interested in stocks on the move can receive Free Alerts by visiting www.pennystockchaser.com
Vancouver, BC, Canada, April 16, 2009 (PRESSbooth.ORG) -- Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) announced its corporate partner, Cook Medical, reported data on two-year follow up that showed that 82 percent of patients who were treated with Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent (DES) were free from reintervention at two-year follow up. The Zilver PTX Registry study, involving 792 patients from across the world, is assessing the safety and efficacy of the Zilver PTX in treating PAD. The most recent results were reported at the 31st International Symposium: Charing Cross Controversies Challenges Consensus.
"These results are extremely encouraging as it's the first time paclitaxel-coated stents have been used in the treatment of blockages in arteries outside the heart," said Zilver PTX global principal investigator, Dr. Michael Dake, Professor in the Department of Cardiothoracic Surgery at Stanford University Medical School and Medical Director of the Cath/Angio Laboratories at Stanford University Medical Center. "Patients treated with the Zilver PTX had a very low complication rate and required fewer reinterventions."
Data was compiled at 12 and 24 months for 593 patients and 177 patients respectively from the registry study, which enrolled a broad spectrum of patients, including those with complex lesions (e.g., long lesions, total occlusions, in-stent restenosis). The corresponding event-free survival (EFS) rates were 87 percent and 78 percent, and freedom from TLR (target lesion revascularization) was 89 percent and 82 percent. Clinical measures that included ankle-brachial index, Rutherford score, and walking distance and speed scores showed significant improvement at six and 12 months and were maintained through 24 months.
Detailed evaluation of stent x-rays demonstrated excellent stent integrity through 12 months, confirming previously published results showing 99 percent completely intact stents with a mean follow up of 2.4 years in the challenging superior femoral artery and popliteal arteries, including behind the knee locations.
One in five in the 65- to 75-year-old age group in the UK* has peripheral arterial disease (PAD). Yet only a quarter of these people have any symptoms at all. The 'silent' nature of this condition can result in a number of patients being diagnosed only when their condition has progressed to the severe stage. In patients with severe PAD whose condition is not improving with risk-factor modification, exercise programs and pharmacological therapy, invasive procedures may need to be carried out. These procedures include angioplasty, stenting or surgery.
"We are impressed with both the efficacy and durability demonstrated by the Zilver PTX in the registry study and believe we will see similar results in the US randomized trial which is currently ongoing," said Dr. Bill Hunter, President and CEO of Angiotech. "Our partner, Cook Medical, has been committed to continually improving the efficacy and safety of peripheral DES and early results suggest that the self-expanding, Zilver PTX stent will be an important treatment option for patients with PAD."
In addition to the registry arm of the study, the 480 patient randomized component is designed to evaluate the Zilver PTX across 45 trial sites in the United States, Japan and Europe. Of the 480 patients enrolled in the randomized study, 240 received the Zilver PTX DES. Enrollment in the randomized study was completed in 2008. For more information, please visit www.zilverptxtrial.com.
* Fowkes FGR, Housley E, Cawood EHH, MacIntyre CAA, Ruckley CV, Prescott RJ. Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991;20:384-91.
Cook licenses the rights to use paclitaxel with peripheral stents and other non-coronary medical devices from Angiotech. Under the terms of its 1997 license agreement with Cook, Angiotech is entitled to ereceive royalty payments upon the commercial sale of paclitaxel-eluting peripheral vascular products, including the Zilver PTX.
About PennyStockChaser.com:
PennyStockChaser.com's alerts are daily e-mails on stocks that are hot in the market. These include stocks with huge volume, penny stocks, new 52 week highs or lows, stocks with technical indicators, and much more. Our stock alerts have done very well in the last couple of weeks.
We encourage investors to subscribe to our Free e-mail alerts by visiting: http://pennystockchaser.com/join-now/
Join today. Read our picks. Get ready to profit.
PennyStockChaser.com is a leading stock website that provides free daily alerts on stocks that are moving up. PennyStockChaser.com also tracks small cap stocks that are on the brink of exploding. We also feature companies on our website with research reports, analysis, and newsletters. To feature a company on our web site please contacts us at editorial @ pennystockchaser.com. The companies that are discussed in this opinion have not approved the statements made in this opinion.
This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.
PennyStockChaser.com is an independent electronic publication that provides information on selected publicly traded companies. PennyStockChaser.com is not a registered investment advisor or broker-dealer. PennyStockChaser.com's affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.
Contact:
PennyStockChaser Editorial Staff
Email: editorial @ pennystockchaser.com
http://pennystockchaser.com
:: 
:: 
::
